Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067807 · ClinicalTrials.gov registry record · Phase 1
Proellex Pharmacokinetics Bridging Study
A Phase 1 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01067807: Completed Phase 1 study, sponsored by Repros Therapeutics.
NCT01067807 is a Phase 1 study that has completed, run by Repros Therapeutics. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01067807, a Phase 1 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Healthy female subjects received a single dose of four different types of Proellex, the original 25 mg dose and three new formulations
Interventions
- DRUG 25 mg Proellex
- DRUG 50 mg Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
What the finished NCT01067807 record still lists
NCT01067807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which 25 mg Proellex is the first listed.
NCT01067807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01067807 about?
NCT01067807 is a clinical study titled "Proellex Pharmacokinetics Bridging Study". Healthy female subjects received a single dose of four different types of Proellex, the original 25 mg dose and three new formulations
What is the current status of trial NCT01067807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2007-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT01067807?
The interventions under investigation include: 25 mg Proellex (DRUG), 50 mg Proellex (DRUG).
Who is sponsoring clinical trial NCT01067807?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01067807's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia